Abstract:Background Checkpoint inhibitors can induce robust and durable responses in a subset of patients. Extending this benefit to more patients could be facilitated by better understanding of how interacts with immune cells with the tumor microenvironment, which is a critical barrier to control both local and systemic disease. The composition and pattern of the immune infiltrate associates with the likelihood of response to immunotherapy. Inflamed tumors that exhibit a brisk immune cell infiltrate are responsive, while those in which immune cells are completely or partially excluded are not. Transforming growth factor β (TGFβ) is immunosuppressive and associated with the immune excluded phenotype. Methods Using an immune competent mammary tumor derived transplant (mTDT) model recently developed in our lab, exhibits inflamed, excluded or deserts immune infiltrate phenotypes based on localization of CD8 lymphocytes. Using whole transcriptome deep sequencing, cytof, and PET-CT imaging, we evaluated the tumor, microenvironment, and immune pathway activation among immune infiltrate phenotypes. Results Three distinct inflamed tumors phenotypes were identified: ‘classically’ inflamed characterized by pathway evidence of increased CD8+ T cells and decreased PD-L1 expression, inflamed tumors with pathways indicative of neovascularization and STAT3 signaling and reduced T cell mobilization, and an inflamed tumor with increased immunosuppressive myeloid phenotypes. Excluded tumors were characterized by TGFβ gene expression and pro-inflammatory cytokine signaling (e.g. TNFα, IL1β), associated with decreased leukocytes homing and increased immune cell death of cells. We visualized and quantified TGFβ activity using PET-CT imaging of 89Zr-fresolimumab, a TGFβ neutralizing antibody. TGFβ activity was significantly increased in excluded tumors compared to inflamed or desert tumors, which was supported by quantitative pathology (Perkin Elmer) of its canonical signaling target, phosphorylated SMAD2 (pSMAD2). pSMAD2 was positively correlated with PD-L1 expression in the stroma of excluded tumors. In contrast, in inflamed tumors, TGFβ activity positively correlated with increased F4/80 positive macrophages and negatively correlated with expression of PD-L1. CyTOF analysis of tumor and spleen immune phenotypes revealed increased trafficking of myeloid cells in mice bearing inflamed tumors compared to excluded and deserts. Conclusions The immunocompetent mTDT provides a model that bridges the gap between the immune landscape and tumor microenvironment. Integration of these high-dimensional data with further studies of response to immunotherapies will help to identify tumor features that favor response to treatment or the means to convert those that are unresponsive.

Change and Its Significance of CD4+ CD25+ Regulatory T Cells in Experimental Murine Mammary Carcinoma Model

The Detection and Its Significance of CD4~+ CD25~(bright) CCR6~+ Treg Regulatory T Cells in Murine Mammary Carcinoma Model

Inhibitory effect of CD4+CD25+CCR6+ regulatory T cells against CD8+T cells in mouse mammary carcinoma model

Expression and significance of CD4+CD25high regulatory T cells in patients with non-small-cell lung cancer

The Dynamic Changes and Significance of T Lymphocyte Subsets During Tumor Progression in Murine Pancreatic Cancer Model

Tumor-infiltrating CD8+ and FOXP3+ Lymphocytes Before and after Neoadjuvant Chemotherapy in Cervical Cancer

[Tumor Infiltrating Regulatory T Cells in Human Breast Cancer and Associated Draining Lymph Nodes: an In-Situ Analysis].

The difference of CD4+CD25+ regulatory T cells and Foxp3 expression in non-small cell lung cancer patients with different lymph node metastasis status

Genome-Wide Analysis of Molecular Changes in IL-12-Induced Control of Mammary Carcinoma Via IFN-γ-Independent Mechanisms

Global Gene Expression Profiling in Interleukin-12-induced Activation of CD8(+) Cytotoxic T Lymphocytes Against Mouse Mammary Carcinoma.

The Profile of CD4+CD25+ T Regulatory Lymphocytes Subpopulation in Patients with Cancer by Flow Cytometry

Standardized approach for evaluating tumor infiltrating lymphocytes in canine mammary carcinoma: Spatial distribution and score as relevant features of tumor malignancy

Interleukin-10 overexpression in 4T1 cells: A gateway to suppressing mammary carcinoma growth

Depletion of CD4+CD25high Regulatory T Cells from Tumor Infiltrating Lymphocytes Predominantly Induces Th1 Type Immune Response in Vivo Which Inhibits Tumor Growth in Adoptive Immunotherapy

In Situ Prior Proliferation of CD4+ CCR6+ Regulatory T Cells Facilitated by TGF-β Secreting DCs is Crucial for Their Enrichment and Suppression in Tumor Immunity.

TGFβ in malignant canine mammary tumors: relation with angiogenesis, immunologic markers and prognostic role

Enrichment of CCR6+Foxp3+ Regulatory T Cells in the Tumor Mass Correlates with Impaired CD8+ T Cell Function and Poor Prognosis of Breast Cancer.

492 Integration of High Dimensional Datasets in an Immunocompetent Mammary Mouse Model Reveals Pathways of Tolerance and Resistance to Immune Checkpoint Blockade

Effective chemoimmunotherapy with anti-TGFβ antibody and cyclophosphamide in a mouse model of breast cancer

Increased CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup> Regulatory T Cells in Cancer Patients from Conversion of CD4<sup>+</sup>CD25<sup>–</sup> T Cells through Tumor-Derived Factors

Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer Predicted by CD4+, CD8+, and FOXP3+ Tumor-Infiltrating Lymphocytes